CLAIMS

1. Use of semaglutide in the manufacture of a medicament for the treatment of mild cognitive impairment or Alzheimer’s disease.

2. Use of semaglutide in the manufacture of a medicament for the treatment of preclinical Alzheimer’s disease, mild cognitive impairment of the Alzheimer’s type, early onset familial Alzheimer's disease, or prodromal Alzheimer's disease.

3. The use according to claim 2, wherein treatment is reducing the risk of developing preclinical Alzheimer’s disease, mild cognitive impairment of the Alzheimer’s type, early onset familial Alzheimer's disease, or prodromal Alzheimer's disease.

4. The use according to claim 1, wherein treatment is reducing the risk of developing Alzheimer’s disease.

5. The use according to any one of the preceding claims, wherein said semaglutide is the sole pharmaceutically active ingredient to be administered to a subject.

6. The use according to any one of the preceding claims, wherein said semaglutide is to be administered subcutaneously, such as in the form of a solution or suspension, and optionally in the form of a solution comprising at least 90% water and with pH in the range of 7.0-9.0.

7. The use according to claims 1-5, wherein said semaglutide is to be administered orally, such as in the form of a tablet.

8. The use according to claim 7, wherein said semaglutide is to be administered in the form of a tablet comprising at least 30% (w/w) salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, such as SNAC.

9. The use according to any one of the preceding claims, wherein said administration of semaglutide is a chronic treatment in which semaglutide is to be administered for at least 12 months, such as for at least 16 months or at least 18 months.

10. Use of semaglutide in the manufacture of a pharmaceutical composition for treating Alzheimer’s disease.

11. Use of semaglutide in the manufacture of a pharmaceutical composition for treating preclinical Alzheimer’s disease, mild cognitive impairment of the Alzheimer’s type, early onset familial Alzheimer's disease, or prodromal Alzheimer's disease

12. The use according to any one of claims 10-11, wherein said use is as defined in any one of claims 3-9.